3 results about "LRP5" patented technology

The application discloses a kind of nanobody specifically binding LRP5 and / or 6 and its application.The nanobody has the ability of selectively targeting and binding LRP5 and / or LRP6, wherein part of the antibody can inhibit the interaction of LRP5 and / or LRP6 with Wnt protein, thereby effectively inhibiting Wnt signaling pathway.The nanobody provided by the application can not only specifically recognize the co-receptor LRP5 and / or LRP6 of Wnt signaling pathway, but also show higher binding affinity, and can be widely applied in the detection of LRP5 and / or LRP6 and related research fields.

Disclosed are a nanobody that specifically binds to LRP5 and / or LRP6 and a use thereof. The nanobody has the ability to selectively target and bind to LRP5 and / or LRP6. Some antibodies can inhibit the interaction between LRP5 and / or LRP6 and Wnt proteins, thereby effectively suppressing the Wnt signaling pathway. The provided nanobody specifically recognizes co-receptors LRP5 and / or LRP6 of the Wnt signaling pathway, exhibits high binding affinity, and can be widely applied to the field of detection and related research of LRP5 and / or LRP6.

To provide a method for treating gastrointestinal disorders using a modified WNT agonist and a modulator of the WNT signaling pathway. [Solution] In one embodiment, the present disclosure includes an engineered WNT agonist comprising (a) one or more binding domains that bind to one or more FZDs; and (b) one or more binding domains that bind to LRP5, LRP6, or both LRP5 and LRP6, wherein the polypeptide sequence has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1 to 18, or a polypeptide sequence disclosed in any one of SEQ ID NOs: 1 to 25, Figure 2, Figure 6, Table 1, or Table 3, or a functional fragment or variant thereof, for example, its binding fragment, for example, a VHH domain, a heavy chain variable domain, or a light chain variable domain.